The research update on cellular immune abnormality in myelodysplastic syndrome--review.
- Author:
Fang XU
1
;
Ting LIU
Author Information
1. Department of Hematology, West China Hospital of Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Cytokines;
blood;
Humans;
Immunosuppressive Agents;
therapeutic use;
Lymphocyte Activation;
Myelodysplastic Syndromes;
drug therapy;
immunology;
Signal Transduction;
T-Lymphocytes;
immunology
- From:
Journal of Experimental Hematology
2003;11(6):673-677
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome is a group of diseases characterized by abnormal clonal proliferation of hematopoietic cells and pancytopenia with dysplasia. The pathogenesis of MDS includes factors of chromosome aberrations, gene mutations, immune abnormalities, environmental changes, and so on. Now it is commonly accepted that MDS is a multistep process disorder involving more etiologic alterations. Recently more and more investigations indicate that the abnormality of cellular immunity is one of important reasons related to MDS. Some proofs about the abnormal activation of T-cell and the abnormal expressions of cytokines in different stages of immune response in MDS have been documented, meanwhile, numerous clinical studies on immune therapy in MDS provide a great number of evidences to disclose its immune abnormalities.
